Oct 12, 2011 | Laboratory News, Uncategorized
Deal may be just the first of more clinical laboratory acquisitions in the U.S by Japan’s largest medical lab testing company
Pathology and clinical laboratory testing companies continue to go global and last week’s big acquisition in anatomic pathology gave one of Japan’s biggest clinical laboratory companies an important foothold in the United States.
Miraca Holdings Inc. (TYO: 4544.T) of Tokyo, Japan, announced that it would acquire the anatomic pathology business of Caris Life Sciences, Inc., of Irving, Texas. Miraca says the purchase is the first ever by a Japanese company of a clinical laboratory testing company in the United States.
(more…)
Jan 25, 2011 | Laboratory News, Laboratory Pathology
Cancer Testing and Molecular Diagnostics Are Main Drivers in This Transaction
In a deal with implications for independent clinical pathology laboratories, pharmaceutical giant Novartis (NYSE: NVS) announced that it would acquire pathology testing company Genoptix, Inc. (NASDAQ: GXDX). Novartis will pay $470 million in cash to acquire all the shares of Genoptix.
Although the total amount of $470 million to be paid for Genoptix is nearly one-half billion dollars, one financial analyst who quickly responded to the news believes that Novartis did not pay a premium price for Genoptix. At William Blair & Company, Analyst Amanda Murphy, CFA, wrote that “…the valuation [of Genoptix] is below what esoteric/specialty labs have been sold for in the past (closer to 10 times or more), which might reflect the company’s recent operational issues and/or potential reimbursement pressure from a shift to in-network status with payers.”
(more…)
